Details for Patent: 5,213,804

Summary for Patent: 5,213,804

Title:	Solid tumor treatment method and composition
Abstract:	A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 .mu.g agent/.mu.mole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.
Inventor(s):	Martin; Francis J. (San Francisco, CA), Woodle; Martin C. (Menlo Park, CA), Redemann; Carl (Walnut Creek, CA), Yau-Young; Annie (Palo Alto, CA)
Assignee:	Liposome Technology, Inc. (Menlo Park, CA)
Application Number:	07/642,321
Patent Claim Types: see list of patent claims	Composition; Dosage form; Compound; Use;

Drugs Protected by US Patent 5,213,804

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,213,804

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0496835		960031	Netherlands
European Patent Office	0496835		SPC/GB96/053	United Kingdom
European Patent Office	0496835		C960031	Netherlands
European Patent Office	0496835		96C0047	Belgium
Austria	115401